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Summary
Objective: Sphingosine-1-phosphate (S1P) is a messenger molecule, with important functions in inﬂammation and wound healing. The
present study was performed to elucidate a possible role of S1P signaling in articular chondrocytes.
Methods: Human and bovine primary chondrocytes were cultured in monolayer. Reverse transcriptase polymerase chain reaction (RT-PCR)
was performed to detect S1P receptor mRNA. Proliferation of S1P stimulated chondrocytes was measured by 3H-thymidine uptake. Super-
natants of cultured bovine chondrocytes stimulated with S1P alone or in combination with interleukin-1b (IL-1b) were tested for nitric oxide
(NO) formation and expression of inducible nitric oxide synthase (iNOS). Matrixmetalloprotease-13 (MMP-13) and aggrecanase-1
(ADAMTS-4) were evaluated using real-time PCR. Glycosaminoglycan (GAG) loss from bovine cartilage explants was evaluated using the
dimethylene blue method.
Results: S1P1, S1P2 and S1P3 but not S1P4 and S1P5 receptor mRNA were detected in human and bovine chondrocytes. S1P dose depen-
dently induced proliferation in bovine and human chondrocytes. S1P signiﬁcantly reduced NO formation and iNOS mRNA and protein expres-
sion, both in un-stimulated and IL-1b stimulated bovine chondrocytes. Furthermore, S1P dose dependently inhibited IL-1b induced expression
of ADAMTS-4 and MMP-13 and diminished IL-1b mediated GAG depletion from cartilage explants.
Conclusion: These results suggest that S1P provides an anti-catabolic signal in articular chondrocytes.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Sphingolipids are important structural elements of cell mem-
branes. In recent years, a growing body of evidence indi-
cates that certain sphingolipid species may also act
as signaling molecules1,2. Among these is sphingosine-1-
phosphate (S1P), which is generated by sphingosine
kinase from the ceramide metabolite sphingosine3. S1P is
released from most cells after stimulation with growth fac-
tors such as transforming growth factor-beta (TGF-b)4. Ad-
ditionally, S1P formation in response to tumor necrosis
factor-alpha (TNF-a) has been reported5. S1P binds to spe-
ciﬁc G protein coupled receptors, of which ﬁve isoforms
(termed S1P1e5) have been identiﬁed
6. S1P is involved in
the regulation of vital functions including cell migration,1Supported by a grant of the Austrian Rheumatologic Society
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305inﬂammation, angiogenesis, and wound healing7e9. S1P
is a potent mitogen for most cells like ﬁbroblasts or osteo-
blasts, although there have been reports that it may inhibit
proliferation in other cell types such as keratinocytes3,10,9.
In endothelial and smooth muscle cells, S1P has been re-
ported to regulate the production of certain cytokines and in-
ﬂammatory modulators such as interleukin-6 (IL-6) and
nitric oxide (NO)11,12. Deregulation of cellular proliferation
and excess of NO formation are hallmarks of cartilage deg-
radation in diseases like osteoarthritis (OA) and rheumatoid
arthritis (RA)13,14. Chondrocytes produce NO in response to
IL-1, TNF-a and bacterial lipopolysaccharides by utilizing in-
ducible nitric oxide synthase (iNOS, NOS2)15,16. High con-
centrations of NO force chondrocytes to undergo
apoptosis17,18. Furthermore, NO inhibits proteoglycan and
collagen II synthesis in chondrocytes, and mice depleted
of iNOS show less cartilage degradation in models of OA
and RA than their wild-type litter mates19e21.
We hypothesize that S1P might inﬂuence cartilage
homeostasis by inﬂuencing proliferation and NO forma-
tion. To elucidate this hypothesis, we investigated the
presence of S1P receptors in chondrocytes. Furthermore,
we evaluated the effect of S1P on proliferation, NO forma-
tion and cartilage proteoglycan degradation in articular
chondrocytes.
306 M. H. Stradner et al.: S1P signaling in chondrocytesMaterials and methodsREAGENTSS1P (Sigma-Aldrich, St. Louis, MO) was dissolved in methanol, evapo-
rated and re-suspended in 0.4% fatty acid free bovine serum albumin
(BSA) (PAA Laboratories, Pasching, Austria). Bovine IL-1b (AbD Serotec,
Oxford, UK) was dissolved in distilled water. Dulbecco’s Modiﬁed Eagle Me-
dium (DMEM), DMEM/F-12 1:1, fetal calf serum (FCS) and Penicilin/Strepto-
mycin/Amphotericin B solution were from PAA Laboratories (Pasching,
Austria). Antibodies against iNOS were from Upstate (Lake Placid, NY)
against actin from Sigma-Aldrich and secondary antibody was purchased
at Cell Signaling (Danvers, MA).CELL AND TISSUE CULTURECartilage explants were harvested from bovine metacarpophalangeal
joints of 3-month-old calves with sterile technique. To obtain chondrocytes
for cell culture, cartilage was minced and digested in 0.2% collagenase B
(F. Hoffman La Roche Ltd., Basel, Switzerland) for 16 h. The resulting cell
suspension was ﬁltered through a nylon mesh with pores of 70 mm (BD
Pharma, Le Pont-De-Claix, France). Cells were counted and viability tested
using trypan blue dye (Sigma-Aldrich, St. Louis, MO). Bovine chondrocytes
were then cultured in monolayer at 37C and 5% CO2, in DMEM/F-12 1:1
supplemented with 10% FCS and 1% Penicilin/Streptomycin/Amphotericin
B solution without further passage and upon 80e90% conﬂuence cultures
were incubated with serum free medium 24 h prior to experiments.
Human cartilage was obtained from patients undergoing hip or knee joint
replacement. Informed consent was given by patients and the protocol was
approved by the ethical committee at the Medical University of Graz. Chon-
drocytes for monolayer culture were attained exactly as described above.
Human chondrocytes were expanded in monolayer over one additional pas-
sage before using them in experiments.
Chondrocyte viability in the presence of 0.01e10 mM S1P or the corre-
sponding amount of vehicle (0.4% fatty acid free BSA; PAA Laboratories,
Pasching, Austria) was assessedusing amodiﬁedXTT (sodium30-[1-phenyl-
aminocarbonyl)-3,4-tetrazolium]bis(4-methoxy-6-nitro)benzenesulfonic acid) as-
say (EZ4U; Biomedica, Vienna, Austria).END-POINT REVERSE TRANSCRIPTASE POLYMERASE
CHAIN REACTION (RT-PCR)RNA was isolated from chondrocytes using Tri-reagent (Sigma-Aldrich,
St. Louis, MO) according to the manufacturers’ recommended protocol. To
avoid potential DNA contamination, DNA was digested with 1 U DNase (Fer-
mentas, Burlington, ON) per mg RNA for 30 min at 37C. A total of 1 mg of
RNA was then reverse transcribed using RevertAid cDNA Synthesis Kit (Fer-
mentas) and random hexamer primers according to the provided manual.
PCR was performed using reagents from High Fidelity PCR Kit (Fermentas)
and primers (MWG, Ebersberg, Germany) designed with Primer3 software22.
Sequences of primers are listed in Table I. PCR was carried out using a Bio-
Rad MyCycler (Bio-Rad Laboratories, Hercules, CA) and 35 cycles of three
steps (95C, 60C, 72C e 30 s duration each) were run. PCR products were
separated by 2% agarose gel electrophoresis and DNA bands were visual-
ized with ethidium bromide.Table
Primer sequ
Forward
Bovine S1P1 5
0-AATTGAGAGCTCGACGCAGT-30
Bovine S1P2 5
0-GAGTCCCGACACGAAGGATA -30
Bovine S1P3 5
0-ACCACCGTGCTGTTCTTGAT-30
Bovine S1P4 5
0-GCTCATCGTCCTGCACTACA -30
Bovine iNOS 50-TGAACGAGGAACAGGTGGA -30
Bovine MMP-13 50-GGTGACTGGCAGACTTGATG-30
Bovine TIMP-1 50-CTCCCTGGAACAGCATGAGT-30
Bovine COX-2 50-TCCATGTCAGAATCGAGGTG-30
Bovine ADAMTS-4 50-GAAGCAATGCACTGGTCTGA-30
Bovine GAPDH 50-GGTGATGCTGGTGCTGAGTA -30
Human S1P1 5
0-TTCTGCGGGAAGGGAGTATGT-30
Human S1P2 5
0-GCGCCATTGTGGTGGAA-30
Human S1P3 5
0-TGATCCTCTACGCACGCATC-30
Human S1P4 5
0-CTTTGCTGGGCTGGAACTG-30
Human S1P5 5
0-TGGACGCTTGCTCCACTGT-30
Human GAPDH 50-CCACATCGCTCAGACACCAT-30CELL PROLIFERATION ASSAYPrior to proliferation experiments, cells cultured in 96 well culture plates
were incubated for 24 h in serum free DMEM. Cells were then treated with
0.1e3 mM S1P. As a negative control 0.4% fatty acid free BSA solution (ve-
hicle) was used. Insulin containing culture supplement (ITS; Becton Dickin-
son, Franklin Lakes, NJ) served as a positive control. During the last 6 h
of culture 1 mCi [methyl-3H]-thymidine (Amersham, Uppsala, Sweden) was
added per ml of media. Cells were harvested to UniFilter-96 GF/C ﬁlter plates
(PerkinElmer, Boston, MA) using a Filter Mate cell harvester (PerkinElmer).
Filter plates were dried for 1 h and 20 ml BetaplateScint (PerkinElmer) scin-
tillation cocktail per well was added. Incorporated radioactivity was measured
with a 1450 Microbeta liquid scintillation counter (LKB-Wallac, Turku,
Finland).DETERMINATION OF GLYCOSAMINOGLYCAN (GAG) LOSSCartilage explants of approximal, 2 mm 2 mm 1 mm, size were
treated with S1P, vehicle control or IL-1b for 72 h. Thereafter explants
were blotted dry, weighed and digested in phosphate buffer (2.76 g/l
NaH2PO4, 0.38 g/l ethylene diamine tetraacetic acid (EDTA), pH 6.8) con-
taining 0.6 g/l papain and 0.25 g/l DL-dithiothreitol (all Sigma-
Aldrich). GAG concentration in culture supernatants and the digested ex-
plants was determined by 1,9-dimethyl-methylene blue (DMB; Sigma-Al-
drich) reaction23. In brief 20 ml of the samples and chondroitin sulfate
(Sigma-Aldrich) standard dilution were incubated with 180 ml DMB solution
(38.5 mM DMB, 40 mM NaCl, 40 mM glycin, 0.5% ethanol, pH 3) for 5 min.
Absorbance at 650 nm was measured with Spectra max 384 plate reader.
Results were normalized to dry weight of the explants for GAG release
and GAG content. For the calculation of the percentage of GAG depletion
to the media values without normalization to cartilage weight were used.NO PRODUCTIONSupernatants of cells treated for 24 h with S1P, vehicle control or IL-1b,
were examined for nitrite, a stable metabolite of NO, using a spectrophoto-
metric method based on the Griess reaction. One-hundred microliters of
the culture supernatants or sodium nitrite standard dilutions were mixed
with 100 ml Griess reagent (1% sulfanilamide, 0.1% naphthyl ethylenedi-
amine dihydrochloride, and 1.25% H3PO4; all Sigma-Aldrich) and incubated
for 10 min at room temperature. Nitrite concentration was determined at
550 nm in a Spectra max 384 plate reader (Molecular Devices, Sunnyvale,
CA). Values are expressed as the micro-molar concentration of nitrite re-
leased per mg total protein.REAL-TIME RT-PCRFor real-timeRT-PCR analysis, cells were treatedwith 0.1e10 mMS1P, ve-
hicle only or 10 ng/ml IL-1b for 3 h. RNA isolation and cDNA synthesis were
performed as described above. For ampliﬁcation a ready to use master mix,
containing SYBR green (Invitrogen Corp., Carlsbad, CA) and primers as
shown in Table I were used. A standard curve was constructed from a pool
of bovine chondrocyte cDNA samples to allow quantiﬁcation. The housekeep-
ing gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as anI
ences
Reverse Size (bp)
50-GGAGAGAGATCCAGGCGTTT-30 172
50-CAGTGTGACTGAACCCGAGA -30 226
50-GAGGCTCAGTGTCCTCTTGC -30 195
50-CTGAGCGTGATGTTCACGAG -30 204
50-AATTGAGAGTGGGTGCCATC -30 199
50-CCACACCTTGAAGGCTTTTC-30 202
50-TCTGGAACCCCTTGTCAGAG-30 174
50-AGTGCACTGTGTTGGGAGTG-30 264
50-GGTCAGCGTCGTAGTCCTTG-30 218
50-GTCTTCTGGGTGGCAGTGAT-30 299
50-TATAGCGCTCAATGGCGATG-30 77
50-GTACATTGCCGAGTGGAACTTG-30 74
50-CGCTCCGAGTTGTTGTGGTT-30 76
50-TGTAGCGCTTGGAGTAGAGGG-30 75
50-AGCACGCAGAAGAGCACGT-30 61
50-ACCAGGCGCCCAATACG-30 70
307Osteoarthritis and Cartilage Vol. 16, No. 3internal control and all samples were run in triplicates. Real-time PCR protocol
consisted of 40 cycles of ampliﬁcation followed by a temperature gradient to
verify ampliﬁed sequences by their melting temperature. Real-time PCR was
performed with AB7900HT (Applied Biosystems, Foster City, CA). The initial
amount of cDNAwas calculated using ABI prism sequence detecting software
(Applied Biosystems) according to themanufacturers’ manual, and was based
on ﬁxed quantities for the standard. The mean quantity of a given triplicate for
the target gene was compared to the mean quantity for the housekeep-
ing gene GAPDH, resulting in a normalized and comparable ratio.WESTERN BLOT ANALYSISTotal proteins were extracted from cultured chondrocytes after 24 h of
treatment with S1P, vehicle control or IL-1b using lysis buffer (50 mM Tri-
seHCl, 4.1 M NaCl, 0.1% Triton X-100, 5 mM EDTA, 1% protease inhibitor
cocktail; all Sigma-Aldrich). After brief sonication protein concentration was
measured with DC Protein assay (Bio-Rad). Protein (7 mg or 20 mg) was sep-
arated by sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) using a 10% polyacrylamide gel and was transferred to a nitrocellu-
lose membrane (Bio-Rad). After overnight blocking in 5% skim-milk in Tris-
buffered saline, the membranes were incubated with primary antibodies
against iNOS (1:2000) and actin (1:5000) for 2 h. Thereafter membranes
were rinsed in blocking solution and incubated for 1 h with secondary anti-
body conjugated to horse radish peroxidase (1:3000). Bands were visualized
using ECL plus detection system (Amersham).25000 **ASTATISTICAL ANALYSIS15000
20000
** **Results are presented as mean standard deviation (SD). Real-time RT-
PCR results are expressed as mean SD percentage over control. Compar-
ison between two groups was done using Student’s t test. Differences be-
tween two groups were considered signiﬁcant at the P< 0.05 level.c
p
mResults
10000CHONDROCYTES EXPRESS RECEPTORS FOR S1P0
5000
vehicle
control
0.1 µM 0.5 µM 1 µM 3 µM
concentration of S1P
12500
15000
B
* **
*Bovine and human chondrocytes were examined for the
presence of S1P receptor mRNA using end-point RT-
PCR. Expression of S1P1, S1P2 and S1P3 was observed
in all samples. The intensity of the S1P1 band was weaker
in bovine samples than in human samples. We could not
detect S1P4 expression in any of the samples tested.
S1P5 mRNA expression was weak in human chondrocytes
and could not be examined in bovine chondrocytes, since
no homologous gene has been identiﬁed in the bovine ge-
nome so far. An example of a typical PCR result is given
in Fig. 1. Negative controls performed with water instead
of template cDNA yielded no signal. GAPDH gene was
used as a positive control.10000
S1P STIMULATES CHONDROCYTE PROLIFERATION7500
c
p
mTreatment of bovine and human chondrocytes with
0.1e10 mM S1P or the corresponding amount of vehicle forA
100 bp - 
GAPDH     S1P1      S1P2     S1P3     S1P4      S1P5
B
GAPDH    S1P1      S1P2      S1P3      S1P4
300 bp - 
200 bp - 
Fig. 1. Expression of S1P receptors in bovine and human articular
chondrocytes. RT-PCR of RNA isolated from bovine (A) and human
(B) chondrocytes grown in monolayer. The data shown are repre-
sentative of six independent samples.up to 48 h did not result in reduced cell viability (data not
shown). Furthermore, stimulation of bovine and human chon-
drocytes with various concentrations of S1P for 24 h led to
a dose dependent increase in chondrocyte proliferation,
measured by [methyl-3H]-thymidine uptake (Fig. 2). Re-
sponse to S1P treatment started at a concentration of
0.5 mM,where a signiﬁcant (P< 0.01) raise of counts permin-
ute (cpm) over vehicle control was observed in bovine chon-
drocytes. Signiﬁcant (P< 0.05) response to S1P in human
chondrocytes was found at 1 mM. The maximum effect of
S1P on chondrocyte proliferation was reached at a concen-
tration of 3 mM, resulting in a doubling of [methyl-3H]-thymi-
dine uptake in bovine chondrocytes and an increase of
61% in human chondrocytes. Comparable uptake rates
were reached in chondrocytes tested in the presence of 1.0
mg/ml insulin from bovine pancreas, 0.55 mg/ml human
transferrin (substantially iron-free), and 0.5 mg/ml sodium sel-
enite (1% ITS culture supplement Becton Dickinson), which
was used as a positive control (data not shown).0
2500
5000
vehicle
control
0.1 µM 0.5 µM 1 µM 3 µM
concentrations of S1P
Fig. 2. Effect of S1P on chondrocyte proliferation. Bovine articular
chondrocytes (A) and human chondrocytes (B) were treated with
the indicated concentrations of S1P for 24 h. The appropriate vol-
ume of vehicle solution (0.4% fatty acid free BSA) was used as
a control. Uptake of 3H-thymidine was measured and is expressed
as cpm. Results are presented as meanSD of two independent
experiments, each performed in six replicates. *P < 0.05 and
**P< 0.01.
308 M. H. Stradner et al.: S1P signaling in chondrocytesS1P DECREASES iNOS EXPRESSIONNO production induced by IL-1b was signiﬁcantly de-
creased by S1P (Fig. 3). Maximum inhibitory effect of S1P
was observed at a concentration of 0.5 mM, reducing IL-1b
induced NO levels by 83 9% (P< 0.05). At higher con-
centrations, however, the effect weakened to a reduction
of 64 5% (3 mM), 60 2% (5 mM) and 62 1% (10 mM),
respectively (all P< 0.05).
To evaluate if decreased production of NO in S1P treated
chondrocytes was caused by reduced iNOS expression, we
measured iNOS mRNA expression using real-time RT-PCR
analysis. In these experiments, S1P decreased iNOS ex-
pression in a dose dependent manner. Maximum suppres-
sion was observed at a concentration of 3 mM S1P,
resulting in 52 29% (meanSD) reduction of basal
iNOS expression.
To investigate the inﬂuence of S1P on iNOS expression in
stimulated chondrocytes, cells were treated with S1P in the
presence of IL-1b (10 ng/ml), a potent inducer of iNOS in
chondrocytes24. As expected, stimulation with IL-1b led to
a 45-fold increase in iNOS expression. This effect was signif-
icantly (P< 0.01) inhibited by S1P [Fig. 4(A)]. At concentra-
tions of 0.1 mM, S1P reduced the stimulatory effect of IL-1b
by 49 9%. Furthermore, concentrations of 0.5 mM S1P re-
duced IL-1b induced iNOS expression to 20 16%
(P< 0.01), rendering the remaining increase by IL-1b over
un-stimulated control to ninefold. Analysis of protein expres-
sion revealed a dose dependent reduction of iNOS, both in
IL-1b induced and naive chondrocytes [Fig. 4(B)].S1P PROTECTS CARTILAGE EXPLANTS FROM IL-1
INDUCED GAG LOSSCartilage explants were treated with S1P alone or in
combination with IL-1b and GAG release to the media
was assessed. Comparison of concentrations from 0.1 to
6 mM of S1P to vehicle control did not yield any signiﬁcant
differences. However, GAG release to the media induced
by IL-1b was signiﬁcantly (P< 0.05) and dose dependently0
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Fig. 3. NO formation in the culture supernatant. Concentration of
nitrite was measured after treatment of bovine chondrocytes with
the indicated concentrations of S1P and 10 ng/ml IL-1b for 24 h.
Chondrocytes treated with IL-1b only were supplemented with the
appropriate volume of vehicle solution (0.4% fatty acid free BSA)
as a control. Values are normalized to total protein. The data are
presented as mean  SD of three independent experiments.
*P< 0.05 vs IL-1b treated vehicle control.inhibited by S1P [Fig. 5(A)]. At S1P concentrations of
6 mM GAG release was reduced to 57 16% compared
to IL-1b treated with vehicle solution only. However, no
signiﬁcant change in GAG content after treatment was
observed [Fig. 5(B)].
To assess the effect of S1P on the expression of genes
involved in GAG homeostasis, we measured mRNA levels
of cyclooxygenase-2 (COX-2), matrixmetalloprotease-13
(MMP-13), tissue inhibitor of metalloproteases (TIMP)-1
and aggrecanase-1 (ADAMTS-4) after treatment of bovine
chondrocytes with IL-1b and S1P. IL-1b induced expression
of MMP-13 and ADAMTS-4 was signiﬁcantly (P< 0.05) and
dose dependently inhibited by S1P concentrations of
0.1e5 mM. S1P treatment did not interfere with IL-1b in-
duced up-regulation of COX-2 or the mRNA expression of
TIMP-1.Discussion
The current study demonstrates that bovine and human
chondrocytes express receptors for S1P and that these
cells proliferate in response to S1P. Furthermore, S1P
counteracts the effect of IL-1b on GAG depletion and NO
formation.
S1P mediated cell proliferation as reported recently in
a rat chondrocyte model25. In contrast to our results in hu-
man and bovine chondrocytes, a different set of S1P recep-
tors was identiﬁed in the rat where S1P4 but not S1P1
receptors were detected. The employment of different re-
ceptors could explain the response to nanomolar concen-
trations of S1P seen in rat chondrocytes while log-fold
higher concentrations were necessary in bovine and human
chondrocytes. Synoviocytes also proliferate in response to
S1P, as reported recently26. In contrast to our ﬁndings in
chondrocytes, however, a weak synoviocyte response to
S1P in nanomolar concentrations was reported, while
higher concentrations had no effect on synoviocyte prolifer-
ation26. The response of the different cell types of the joint
to different concentrations of the same mediator could re-
ﬂect physiological differences.
S1P signiﬁcantly inhibited NO formation induced by IL-1b.
The resulting doseeresponse curve revealed a maximum
response at concentrations of 0.5 mM S1P. Similar dosee
response curves in S1P signaling have been reported by
others27. Furthermore, the mRNA expression pattern of
iNOS closely resembled NO formation in the culture super-
natant. Thus, S1P signaling inhibits IL-1b induced iNOS
transcription. These ﬁndings are in line with previous re-
ports of S1P diminishing IL-1 induced iNOS expression in
renal mesangial cells28. Interestingly, the authors reported
that S1P exerted this effect via the Smad signaling path-
way, which is known to be the downstream signaling device
of the anabolic cytokine TGF-b28.
In contrast to chondrocytes where S1P inhibits some of
the effect of exogenous IL-1b, Kitano et al.29 reported that
S1P enhanced IL-1b induced COX-2 expression and pros-
taglandin E2 (PGE2) synthesis in human synoviocytes
26. In-
terestingly, a marked inhibition of NO formation leads to the
activation of COX-2 and enhanced PGE2 production. The
obvious divergence in response between these cell types
of the joint could therefore result in a synergistic effect on
PGE2 accumulation
30.
In cartilage explants GAG depletion induced by IL-1b was
signiﬁcantly reduced in the presence of S1P. Since IL-1 in-
duces degradation of cartilage extra cellular matrix via the
expression of MMPs and aggrecanases in chondrocytes,
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Fig. 4. Effect of S1P on iNOS expression of bovine chondrocytes. iNOS mRNA was quantiﬁed by real-time RT-PCR after 3 h of treatment with
the indicated concentrations of S1P alone (A) or in combination with 10 ng/ml IL-1b (B). Chondrocytes not treated with S1P were supple-
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309Osteoarthritis and Cartilage Vol. 16, No. 3we became interested in the expression of these genes31.
S1P reduces the expression of MMPs while it increases
TIMP-1 expression in dermal ﬁbroblasts and renal mesan-
gial cells28,4. We did not see any effect of S1P on TIMP-1
mRNA expression in bovine chondrocytes (data not
shown). However, we found that S1P signiﬁcantly and
dose dependently inhibited IL-1b induced MMP-13 and
ADAMTS-4 expression (Fig. 6). This is in accordance with
a recent report showing the importance of ADAMTS-4 forGAG depletion32. Diminished expression of MMP-13 and
ADAMTS-4 may therefore well account for the reduced deg-
radative effect of IL-1b in the presence of S1P.
An obvious limitation of our study is the use of chondrocyte
monolayer culture.Chondrocytes growing inmonolayers differ
in multiple aspects from chondrocytes residing in vital carti-
lage. Therefore, results obtained in this study may not exactly
reﬂect the in vivo situationandadditional studies in humancar-
tilageare needed to evaluate the relevance ofS1Psignaling in
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GAG released to the culture supernatant (A) and GAG content of explants (B) was assessed using the DMB method. Values were normalized
to cartilage weight. Results are presented as means (n¼ 6)SD. *P< 0.05 and **P< 0.01.
310 M. H. Stradner et al.: S1P signaling in chondrocytesdiseased joints. Interestingly, S1P has recently been impli-
cated in human joint pathology by the ﬁnding that micro-molar
concentrations of S1P are present in the synovial ﬂuid of pa-
tients suffering from RA26. Such concentrations of S1P would0%
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experiments. *P< 0.05 and **P< 0.01stimulate chondrocyte growth and counteract IL-1 induced
cartilage damage and NO formation. The obvious failure of
such repair mechanisms in joint disorders requires further
investigations of S1P function in diseased cartilage. These0%
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311Osteoarthritis and Cartilage Vol. 16, No. 3considerations could add new aspects to our understanding of
cartilage biology and will have implications for the use of
upcoming S1P agonistic drugs like FTY720 (Fingolimod) for
immunosuppression in RA or multiple sclerosis33,34. Taken
together, we show that signaling via S1P is of functional
signiﬁcance in human and bovine chondrocytes.References
1. Futerman AH, Hannun YA. The complex life of simple sphingolipids.
EMBO 2004;5:777e82.
2. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer
pathogenesis and treatment. Nat Rev Cancer 2004;4:604.
3. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger
in cell proliferation induced by PDGF and FCS mitogens. Nature
1993;365:557.
4. Yamanaka M, Shegogue D, Pei H, Bu S, Bielawska A, Bielawski J, et al.
Sphingosine kinase 1 (SPHK1) is induced by transforming growth fac-
tor-{beta} and mediates TIMP-1 up-regulation. J Biol Chem 2004;279:
53994e4001.
5. Xia P, Wang L, Gamble JR, Vadas MA. Activation of sphingosine kinase
by tumor necrosis factor-alpha inhibits apoptosis in human endothelial
cells. J Biol Chem 1999;274:34499e505.
6. Kluk MJ, Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-
family of G-protein-coupled receptors. Biochim Biophys Acta (BBA) e
Mol Cell Biol Lipids 2002;1582:72.
7. Wang F, Van Brocklyn JR, Hobson JP, Movafagh S, Zukowska-
Grojec Z, Milstien S, et al. Sphingosine 1-phosphate stimulates
cell migration through a Gi-coupled cell surface receptor. Potential
involvement in angiogenesis. J Biol Chem 1999;274:35343e50.
8. Liu Y, Wada R, Yamashita T, Mi Y, Deng C-X, Hobson JP, et al.
Edg-1, the G protein-coupled receptor for sphingosine-1-phos-
phate, is essential for vascular maturation. J Clin Invest 2000;
106:951e61.
9. Vogler R, Sauer B, Kim D-S, Schafer-Korting M, Kleuser B. Sphingo-
sine-1-phosphate and its potentially paradoxical effects on critical pa-
rameters of cutaneous wound healing. J Invest Dermatol 2003;120:
693e700.
10. Grey A, Xu X, Hill B, Watson M, Callon K, Reid IR, et al. Osteoblastic
cells express phospholipid receptors and phosphatases and prolifer-
ate in response to sphingosine-1-phosphate. Calcif Tissue Int 2004;
74:542.
11. Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP,
et al. Sphingosine 1-phosphate modulates human airway smooth
muscle cell functions that promote inﬂammation and airway remodel-
ing in asthma. FASEB J 2001;15:1212e4.
12. De Palma C, Meacci E, Perrotta C, Bruni P, Clementi E. Endothelial ni-
tric oxide synthase activation by tumor necrosis factor {alpha} through
neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1
phosphate receptors. A novel pathway relevant to the pathophysiol-
ogy of endothelium. Arterioscler Thromb Vasc Biol 2005;99e105.
13. Aigner T, Hemmel M, Neureiter D, Gebhard PM, Zeiler G, Kirchner T,
et al. Apoptotic cell death is not a widespread phenomenon in normal
aging and osteoarthritis human articular knee cartilage: a study of pro-
liferation, programmed cell death (apoptosis), and viability of chondro-
cytes in normal and osteoarthritic human knee cartilage. Arthritis
Rheum 2001;44:1304e12.
14. Studer R, Jaffurs D, Stefanovic-Racic M, Robbins PD, Evans CH. Nitric
oxide in osteoarthritis. Osteoarthritis Cartilage 1999;7:377.
15. Stadler J, Stefanovic-Racic M, Billiar TR, Curran RD, McIntyre LA,
Georgescu HI, et al. Articular chondrocytes synthesize nitric oxide in re-
sponse to cytokines and lipopolysaccharide. J Immunol 1991;147:
3915e20.16. Goodstone NJ, Hardingham TE. Tumour necrosis factor {alpha} stimu-
lates nitric oxide production more potently than interleukin-1{beta} in
porcine articular chondrocytes. Rheumatology 2002;41:883e91.
17. Clancy R, Rediske J, Koehne C, Stoyanovsky D, Amin A, Attur M, et al.
Activation of stress-activated protein kinase in osteoarthritic cartilage:
evidence for nitric oxide dependence. Osteoarthritis Cartilage 2001;9:
294.
18. Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis in-
duced by nitric oxide. Am J Pathol 1995;146:75e85.
19. Van de Loo FAJ, Arntz OJ, Van den Berg WB. Effect of interleukin-1 and
leukemia inhibitory factor on chondrocyte metabolism in articular car-
tilage from normal and interleukin-6-deﬁcient mice: role of nitric oxide
and IL-6 in the suppression of proteoglycan synthesis. Cytokine 1997;
9:453.
20. Cao M, Westerhausen-Larson A, Niyibizi C, Kavalkovich K,
Georgescu HI, Rizzo CF, et al. Nitric oxide inhibits the synthesis of
type-II collagen without altering Col2A1 mRNA abundance: prolyl hy-
droxylase as a possible target. Biochem J 1997;(Pt 1):305e10.
21. van denBergWB, van de LooF, Joosten LAB, ArntzOJ. Animalmodels of
arthritis in NOS2-deﬁcient mice. Osteoarthritis Cartilage 1999;7:413.
22. Primer3 on the WWW for General Users and for Biologist Programmers.
Humana Press, 2000. Accessed at, <http://frodo.wi.mit.edu/cgi-bin/-
primer3/primer3_www.cgi>.
23. Farndale RW,Sayers CA, Barrett AJ. A direct spectrophotometricmicroas-
say for sulfated glucosaminoglycans in cartilage cultures. Connect Tis-
sue Res 1982;9:247e8.
24. Palmer RMJ, Hickery MS, Charles IG, Moncada S, Bayliss MT. Induc-
tion of nitric oxide synthase in human chondrocytes. Biochem Biophys
Res Commun 1993;193:398.
25. Kim M-K, Lee HY, Kwak J-Y, Park J-I, Yun J, Bae Y-S. Sphingosine-1-
phosphate stimulates rat primary chondrocyte proliferation. Biochem
Biophys Res Commun 2006;345:67.
26. Kitano Masayasu, Hla Timothy, Sekiguchi Masahiro, Kawahito Yutaka,
Yoshimura Rikio, Miyazawa Keiji, et al. Sphingosine 1-phosphate/-
sphingosine 1-phosphate receptor 1 signaling in rheumatoid syno-
vium: regulation of synovial proliferation and inﬂammatory gene
expression. Arthritis Rheum 2006;54:742e53.
27. Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory
and stimulatory regulation of Rac and cell motility by the G12/13-Rho
and Gi pathways integrated downstream of a single G protein-
coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol
2003;23:1534e45.
28. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, et al.
Sphingosine 1-phosphate cross-activates the Smad signaling cas-
cade and mimics transforming growth factor-{beta}-induced cell re-
sponses. J Biol Chem 2004;279:35255e62.
29. Mathy-Hartert M, Deby-Dupont GP, Reginster JYL, Ayache N, Pujol JP,
Henrotin YE. Regulation by reactive oxygen species of interleukin-
1[beta], nitric oxide and prostaglandin E2 production by human chon-
drocytes. Osteoarthritis Cartilage 2002;10:547.
30. MastbergenSC,BijlsmaJWJ,Lafeber FPJG.Synthesis and releaseof hu-
man cartilagematrix proteoglycans are differently regulated by nitric ox-
ide and prostaglandin-E2. AnnRheumDis 2007; doi:10.1136/ard.2006.
065946.
31. Takahashi N, Rieneck K, van der Kraan PM, van Beuningen HM,
Vitters EL, Bendtzen K, et al. Elucidation of IL-1/TGF-[beta] interac-
tions in mouse chondrocyte cell line by genome-wide gene expres-
sion. Osteoarthritis Cartilage 2005;13:426.
32. Song Ruo-Hua, Tortorella Micky D, Malfait Anne-Marie, Alston James
T, Yang Zhiyong, Arner Elizabeth C, et al. Aggrecan degradation in
human articular cartilage explants is mediated by both ADAMTS-4
and ADAMTS-5. Arthritis Rheum 2007;56:575e85.
33. Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immuno-
suppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Im-
munopharmacol 2000;22:323.
34. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al.
Oral ﬁngolimod (FTY720) for relapsing multiple sclerosis. N Engl J
Med 2006;355:1124e40.
